Ianalumab reduces Sjögren disease activity

Sarah Onuora
Nature Reviews Rheumatology · Springer Nature · 2026-11-10 · DOI: 10.1038/s41584-026-01466-3

Abstract

Nature Reviews Rheumatology, Published online: 10 November 2026; doi:10.1038/s41584-026-01466-3 In patients with active Sjögren disease, treatment with ianalumab 300 mg monthly reduced disease activity, but not symptom scores, more than placebo in two phase III clinical trials.

Read at publisher →

Similar articles